@uriahz@michaelpresky@SteveOnSpeed I’m in Utah. Broke my leg last year with surgery, we had a baby in November, I had an mri/blood work done last month for side pain. It’s actually been a busy year with doctors appointments.
I’m American. I broke my leg last year and had surgery, I think I paid $400 max out of pocket for it. I get it’s different for everyone but there’s also many misconceptions. I work in tech, so my company covers 100% of the insurance and puts $2k a year into has for other expenses. I pay a couple hundred a month to add my wife and son to my insurance. All I’m saying is we pay for insurance and they pay more in taxes.
It’s not even what money can buy. In America, you have a job, job gives you health insurance. You get better care with zero wait in America. I hate when people say free healthcare as they pay much more in taxes. Both have their benefits so not sure why people debate it or care. I’ve been to almost every country in Europe and have heard the good and bad. We in the USA have our good and bad.
As cancer rates continue to rise worldwide, it’s frustrating to see the U.S. fall behind on potentially groundbreaking cancer treatments.
ImmunityBio’s innovative approach is gaining recognition internationally, with countries and regions such as Europe, Saudi Arabia, and Macau moving forward while U.S. patients continue to wait for broader access.
It raises important questions about whether our regulatory system is moving fast enough to support innovation. Are bureaucratic hurdles slowing down access to life-changing therapies? Is the influence of large pharmaceutical interests playing a role in how quickly new treatments reach patients?
The U.S. has historically led the world in biotechnology and medical innovation. But if we continue to create barriers for emerging biotech companies, leadership in this critical field could shift to countries like China that are aggressively investing in the future of medicine.
Patients deserve access to promising treatments, and innovation should be encouraged—not delayed.
@US_FDA@RobertKennedyJr@realDonaldTrump
As we feared. The world and the global leadership need to address this non-infectious pandemic called cancer. Immunotherapy and cell therapy at scale is a response that is needed. Global scale.
https://t.co/EalXc1gq4L
As we feared. The world and the global leadership need to address this non-infectious pandemic called cancer. Immunotherapy and cell therapy at scale is a response that is needed. Global scale.
https://t.co/EalXc1gq4L
Unfortunately I think we’ll be waiting a while for the FDA. Big pharma owns them. We’ve seen countless big pharma drugs with worse results get approved, same studies. That’s why the good doctor is focused on global expansion outside of the U.S. Prove me wrong @US_FDA@RobertKennedyJr